Objectives: The aim of this cross-sectional study was to evaluate the value of prostate-specific antigen (PSA) testing as a tool for early detection of prostate cancer (PCa) applied by general practitioners (GPs) and internal specialists (ISs) as well as to assess criteria leading to the application of PSA-based early PCa detection. Methods: Between May and December 2012, a questionnaire containing 16 items was sent to 600 GPs and ISs in the federal state Brandenburg and in Berlin (Germany). The independent influence of several criteria on the decision of GPs and ISs to apply PSA-based early PCa detection was assessed by multivariate logistic regression analysis (MLRA). Results: 392 evaluable questionnaires were collected (return rate 65%). 81% of the physicians declared that they apply PSA testing for early PCa detection; of these, 58 and 15% would screen patients until the age of 80 and 90 years, respectively. In case of a pathological PSA level, 77% would immediately refer the patient to a urologist, while 13% would re-assess elevated PSA levels after 3-12 months. Based on MLRA, the following criteria were independently associated with a positive attitude towards PSA-based early PCa detection: specialisation (application of early detection more frequent for GPs and hospital-based ISs) (OR 3.12; p < 0.001), physicians who use exclusively GP or IS education (OR 3.95; p = 0.002), and physicians who recommend yearly PSA assessment after the age of 50 (OR 6.85; p < 0.001). Conclusions: GPs and ISs frequently apply PSA-based early PCa detection. In doing so, 13% would initiate specific referral to a urologist in case of pathological PSA values too late. Improvement of this situation could possibly result from specific educational activities for non-urological physicians active in fields of urological core capabilities, which should be guided by joint boards of the national associations of urology and general medicine.

Keywords:
Prostate cancer, Early detection, Prostate-specific antigen , General practitioners, Internal specialists, Continuing education
1.
Leitlinienprogramm Onkologie. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Version 2.0, 1. Aktualisierung 09.2011.
2.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-990.
3.
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team: Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125-132.
4.
Screening for Prostate Cancer, Topic Page. U.S. Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/prostatecancerscreening.htm.
6.
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F; European Association of Urology: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.
7.
Williams N, Hughes LJ, Turner EL, Donovan JL, Hamdy FC, Neal DE, Martin RM, Metcalfe C: Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. BJU Int 2011;108:1402-1408.
8.
Tasian GE, Cooperberg MR, Potter MB, Cowan JE, Greene KL, Carroll PR, Chan JM: PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer Prostatic Dis 2012;15:189-194.
9.
Volk RJ, Linder SK, Kallen MA, Galliher JM, Spano MS, Mullen PD, Spann SJ: Primary care physicians' use of an informed decision-making process for prostate cancer screening. Ann Fam Med 2013;11:67-74.
10.
Hayat Roshanai A, Nordin K, Berglund G: Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer. Acta Oncol 2013;52:1602-1608.
11.
Braun KP, May M, Grassmel Y, Führer S, Hoschke B, Braun V: The general practitioner's part in the initiation of diagnostic procedures in prostate cancer. Aktuelle Urol 2008;39:141-146.
12.
Braun KP, Brookman-Amissah S, May M, Grassmel Y, Hoschke B, Braun V: The assessment of pathological PSA values by the general practitioner - observation or intervention? Aktuelle Urol 2009;40:171-174.
13.
Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H: Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-732.
14.
Durham J, Low M, McLeod D: Screening for prostate cancer: a survey of New Zealand general practitioners. N Z Med J 2003;116:U476.
15.
Little B, Ho KJ, Gormley G, Young M: PSA testing in general practice. Prostate Cancer Prostatic Dis 2003;6:154-158.
16.
Melia J, Moss S, Johns L; Contributors in the participating laboratories: Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 2004;94:51-56.
17.
Jønler M, Eddy B, Poulsen J: Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark. Scand J Urol Nephrol 2005;39:214-218.
18.
Brett J, Watson E, Hewitson P, Bukach C, Edwards A, Elwyn G, Austoker J: PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK. BMC Fam Pract 2005;6:24.
19.
Rochester MA, Donaldson PJ, McLoughlin J: Perception of abnormal serum prostate-specific antigen (PSA) test results amongst family practitioners. Ann R Coll Surg Engl 2008;90:398-402.
20.
D'Ambrosio GG, Campo S, Cancian M, Pecchioli S, Mazzaglia G: Opportunistic prostate-specific antigen screening in Italy: 6 years of monitoring from the Italian general practice database. Eur J Cancer Prev 2010;19:413-416.
21.
van der Meer S, Kollen BJ, Hirdes WH, Steffens MG, Hoekstra-Weebers JE, Nijman RM, Blanker MH: Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners. BJU Int 2013;112:26-31.
22.
Lent V, Baumbusch F, Weber B: Criteria for errors in prostate-specific antigen diagnostics. Urologe A 2012;51:1558-1561.
23.
Nicolaiew N, Ploussard G, Chun FKH, Xylinas E, Allory Y, Salomon L, de la Taille A: Prediction of the risk of harboring prostate cancer by a prebiopsy nomogram based on extended biopsy protocol. Urol Int 2013;90:306-311.
24.
Okihara K, Mikami K, Kamoi K, Kitamura K, Kawauchi A, Miki T: Assessment of screenees' knowledge on prostate cancer: results of a questionnaire using the fact sheet. Urol Int 2013;91:49-54.
25.
Torky M, Mosharafa A, Emran A, Kamal A, Abdelhamid M: Antimicrobial therapy for asymptomatic patients with elevated prostate-specific antigen: can the change in prostate-specific antigen reliably guide prostate biopsy decisions? Urol Int 2011;87:416-419.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.